Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases

• Status: Active, not recruiting
• Trial end date: 2026-12-31

Summary

The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a limited bone metastatic prostate cancer. In addition the influence of patient- and disease-related factors on clinical outcome (prognostic effect) and on the comparison therapy (predictive effect) will be examined.

Amendment05: Due to the slow tumor biology of prostate cancer, the follow-up period of 5 years is not sufficient to reach the primary endpoint of the study. For this reason, the follow-up is extended for a further 5 years with 2 visits per year.

• Phase: N/A

Details

• Lead Sponsor: Martini-Klinik am UKE GmbH
• Collaborator: Förderverein Hilfe bei Prostatakrebs e.V.
• Treatments: Androgens; Ascorbic Acid; Estrogens, Conjugated (USP); Hormones; Methyltestosterone